Group 1 - The core viewpoint of the article highlights that Weili Medical (603309) has seen a stock price increase of 4.18%, closing at 14.94 yuan as of February 6, 2026, compared to 14.34 yuan the previous week [1] - The company achieved a total market capitalization of 4.361 billion yuan, ranking 88th out of 129 in the medical device sector and 3870th out of 5186 in the A-share market [1] - The highest intraday price recorded for Weili Medical during the week was 14.99 yuan, while the lowest was 13.85 yuan [1] Group 2 - Weili Medical announced that multiple products have received EU MDR certification, allowing them to be sold in the European market [1] - The certified products include a range of medical devices such as urinary catheter care kits, drainage bags, puncture guides, and various types of catheters and tubes [1] - The certification was issued by TÜV SÜD Product Service GmbH, with a validity period until May 15, 2028, or December 5, 2028, confirming compliance with the latest EU medical device regulations [1]

截至2026年2月5日收盘，维力医疗(603309)报收于14.57元，上涨1.25%，换手率1.79%，成交量5.22万 手，成交额7583.19万元。 当日关注点 交易信息汇总资金流向 来自交易信息汇总：2月5日主力资金净流出32.41万元，游资资金净流入37.05万元。 来自公司公告汇总：维力医疗多个产品获得欧盟MDR认证，具备在欧盟市场合法销售的准入条 件。 广州维力医疗器械股份有限公司于近日收到欧盟公告机构通知，公司多个产品获得欧盟MDR认证，包 括导尿管护理包、引流罐、穿刺导向器、微网雾化器、振动筛孔雾化器、冲水泵、泵管组件、胃管、人 工鼻、导引针、多通道内窥镜接头、导尿包、亲水乳胶导尿管、亲水硅胶导尿管、肾造瘘管、胃造瘘管 及营养管。认证证书由TÜV SÜD Product Service GmbH签发，签批时间为2026年2月3日，有效期至2028 年5月15日或2028年12月5日。上述产品获证表明其符合欧盟最新医疗器械法规要求，具备在欧盟市场合 法销售的准入条件。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...